Myriad Genetics (MYGN) Liabilities and Shareholders Equity (2010 - 2026)

Myriad Genetics has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $673.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 33.04% year-over-year to $673.7 million; the TTM figure through Mar 2026 stood at $2.8 billion (down 33.68% YoY), while the FY2025 annual figure was $706.6 million, down 31.24% from the prior year.
• Liabilities and Shareholders Equity slipped to $673.7 million in Q1 2026, from $706.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MYGN reached as high as $1.3 billion in Q1 2022 and fell as low as $673.7 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.1 billion (2024), against an average of $1.0 billion.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity declined 1.9% — and 2025, when it slumped 37.58%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.2 billion in 2022, then retreated by 4.35% to $1.1 billion in 2023, then declined by 10.37% to $1.0 billion in 2024, then tumbled by 31.24% to $706.6 million in 2025, then slipped by 4.66% to $673.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $673.7 million, $706.6 million, and $728.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.